Binding assay description

Radioligand binding assays are a relatively simple but at the same time a very important and efficient tool to study target-ligand interactions. Since they are very videly used in drug discovery and have been described extensively, this section only discusses their fundamental aspects and those aspects that are important for the description of the MS binding assays below . More detailed information can be found in the relevant literature [6, 7, 16-21]. 

Purlnerglc receptors - Receptors for the purines may be divided into P-1 and P-2 subtypes. P-1 receptors are adenosine-sensitive and cyclase-linked, while P-2 receptors are ATP-sensltlve, affect prostaglandin synthesis, and have no effect on cyclic AMP production. Two subtypes of the P-1 receptor exist he A-1 or R1 and A-2 or Ra, which, respectively, inhibit or activate adenylate cyclase. Both A-1 and A-2 receptors are sensitive to blockade by xanthines such as caffeine and theophylline. To date, ligand binding assays have only been described for the A-l and P-2 receptors. Binding studies have led to the description of further subtypes which show species... 

Figure 7.7 (A) AFM analysis of a porous anodic alumina (PAA) layer chip surface after Au deposition. (B) Detection of a sandwich-type binding assay between the aptamers and thrombin using Au-capped oxide nanostructures on the PAA layer chip. (C) Relative reflected intensity characteristics of (black line) a bare PAA layer chip, 10 p.M aptamer I immobilized on a gold-deposited PAA layer surface (red line), the binding reaction between 10 p.M aptamer I and 1 p.M thrombin on the chip surface (blue line), after the binding reaction between aptamer I/thrombin complex and aptamer II (green line). (See text for full description.)...

A number of ACE assays dealing with the characterization of interactions between cyclodextrines as auxiliary substances and drugs have been presented. Other authors put more emphasis on the description of separation phenomenona by determination of binding constants. Model substances such as phenols are often used to examine the influence of ligand size and substitution as well as to evaluate the mathematical approaches for the calculation of binding constants. 

The most common, but by no means the only or even the most promising, immunochemical assay for small molecules is radioimmunoassay (R1A). As an overview, an immunoassay involves chemically attaching the small molecule of interest (or a derivative of it) to a carrier protein and raising specific antibody titers to it in the serum of an animal. Very dilute antibody solutions are then used to bind the small molecule which has been radiolabeled. The competition of varying known concentrations of unlabeled material is measured and the resulting standard curve used to determine unknown concentrations (Table 1). The steps leading to the development of an R1A are outlined below followed by a description of other immunochemical procedures and an analysis of the attributes and limitations of immunoassay. 

In the kinetic studies of the adsorption process, the mass transport of the analyte to the binding sites is an important parameter to account for. Several theoretical descriptions of the chromatographic process are proposed to overcome this difficulty. Many complementary experiments are now needed to ascertain the kinetic measurements. Similar problems are found in the applications of the surface plasmon resonance technology (SPR) for association rate constant measurements. In both techniques the adsorption studies are carried out in a flow system, on surfaces with immobilized ligands. The role of the external diffusion limitations in the analysis of SPR assays has often been mentioned, and the technique is yet considered as giving an estimate of the adsorption rate constant. It is thus important to correlate the SPR data with results obtained from independent experiments, such as those from chromatographic measurements. 

A brief description of techniques used in EIA follows. The various assays have been classified as either competitive or noncompetitive assays, depending on whether or not the technique involves a reaction step in which unlabeled and labeled antigen compete for a limited number of antibody sites (competitive assay) or whether the antigen (or antibody) to be measured is first allowed to react with antibody (antigen) on a solid phase followed by measurement of the binding of enzyme-labeled immune reactant (noncompetitive assay)... 

The most widely used technique for the evaluation of hERG channel interaction is the voltage clamp. A detailed description of the experimental setup has been described elsewhere [119]. The hERG interaction is measured and reported as the % inhibition of the hERG current compared to the vehicle control at various concentrations of the NCE. The concentration that inhibits 50% (IC50) is calculated, whenever possible. The concentrations of NCE used in the assay are carefully selected based on the expected maximum plasma concentration (Cmax) at the pharmacologically active dose (usually based on studies in animal models) and the human plasma protein binding for the NCE. 

---